Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses

Vaccine

Volumn 29, Issue 20, 2011, Pages 3695-3702

  Li, Shanfeng ^a   Peng, Liang ^a   Zhao, Wei ^a   Zhong, Hua ^a   Zhang, Fuchun ^b   Yan, Ziqiang ^c   Cao, Hong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Guangzhou Eighth People's Hospital   (China)

^c Guangzhou Municipal Center for Disease Control and Prevention   (China)

Author keywords

Dengue; Domain III; Multi epitope peptide; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DENGUE VACCINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 4; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; BIOINFORMATICS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENGUE VIRUS 2; DRUG DESIGN; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VERO CELL; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; RNA, VIRAL; VACCINES, SUBUNIT; VERO CELLS;

EID: 79955098209     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.002     Document Type: Article

References (46)

1. Guzman M.G., Kouri G. Dengue: an update. Lancet Infect Dis 2002, 2:33-42.
2. Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007, 5:518-528.
3. Stephenson J.R. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 2005, 83:308-314.
4. Gubler D.J., Clark G.G. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1995, 1:55-57.
5. Halstead S.B. Pathogenesis of dengue: challenges to molecular biology. Science 1988, 239:476-481.
6. Thomas S.J., Hombach J., Barrett A. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 2009, 27:355-368.
7. Clyde K., Kyle J.L., Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 2006, 80:11418-11431.
8. Guy B., Almond J.W. Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 2008, 31:239-252.
9. Welsh R.M., Fujinami R.S. Pathogenic epitopes, heterologous immunity and vaccine design. Nat Rev Microbiol 2007, 5:555-563.
10. Webster D.P., Farrar J., Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis 2009, 9:678-687.
11. Khanam S., Khanna N., Swaminathan S. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 2006, 24:6513-6525.
12. Sim A.C., Lin W., Tan G.K., Sim M.S., Chow V.T., Alonso S. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen. Vaccine 2008, 26:1145-1154.
13. Khanam S., Pilankatta R., Khanna N., Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 2009, 27:6011-6021.
14. Miller N. Recent progress in dengue vaccine research and development. Curr Opin Mol Ther 2010, 12:31-38.
15. Roehrig J.T., Johnson A.J., Hunt A.R., Bolin R.A., Chu M.C. Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic conformation. Virology 1990, 177:668-675.
16. Etemad B., Batra G., Raut R., Dahiya S., Khanam S., Swaminathan S., et al. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg 2008, 79:353-363.
17. Khan A.M., Miotto O., Nascimento E.J., Srinivasan K.N., Heiny A.T., Zhang G.L., et al. Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS Negl Trop Dis 2008, 2:e272.
18. Mirshahidi S., Kramer V.G., Whitney J.B., Essono S., Lee S., Dranoff G., et al. Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine 2009, 27:1825-1833.
19. Strohmaier K., Franze R., Adam K.H. Location and characterization of the antigenic portion of the FMDV immunizing protein. J Gen Virol 1982, 59:295-306.
20. Franke E.D., Hoffman S.L., Sacci J.J., Wang R., Charoenvit Y., Appella E., et al. Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. Vaccine 1999, 17:1201-1205.
21. Chianese-Bullock K.A., Lewis S.T., Sherman N.E., Shannon J.D., Slingluff C.J. Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine 2009, 27:1764-1770.
22. Spearman P., Kalams S., Elizaga M., Metch B., Chiu Y.L., Allen M., et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 2009, 27:243-249.
23. Muderspach L., Wilczynski S., Roman L., Bade L., Felix J., Small L.A., et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000, 6:3406-3416.
24. van Driel W.J., Ressing M.E., Kenter G.G., Brandt R.M., Krul E.J., van Rossum A.B., et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999, 35:946-952.
25. Perera R., Kuhn R.J. Structural proteomics of dengue virus. Curr Opin Microbiol 2008, 11:369-377.
26. Konishi E., Kosugi S., Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 2006, 24:2200-2207.
27. Mota J., Acosta M., Argotte R., Figueroa R., Mendez A., Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 2005, 23:3469-3476.
28. Thomas S.J., Nisalak A., Anderson K.B., Libraty D.H., Kalayanarooj S., Vaughn D.W., et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 2009, 81:825-833.
29. Babu J.P., Pattnaik P., Gupta N., Shrivastava A., Khan M., Rao P.V. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine 2008, 26:4655-4663.
30. Guzman M.G., Hermida L., Bernardo L., Ramirez R., Guillen G. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 2010, 9:137-147.
31. Zhong H., Zhao W., Peng L., Cao H. Bioinformatics analysis and characteristics of envelop glycoprotein E epitopes of dengue virus. J Biomed Sci Eng 2009, 2:123-127.
32. Brandt W.E., Cardiff R.D., Russell P.K. Dengue virions and antigens in brain and serum of infected mice. J Virol 1970, 6:500-506.
33. Li S.F., Zhao W., Cao H., Zhang W.B., Peng L., Hao X.Y., et al. Establishment of dengue virus infection model in C57BL/6J mice. Chin J Public Health 2010, 26:586-587.
34. Liu Y., Hu R., Zhang S., Zhang F., Li Z., Wei X., et al. Expression of the foot-and-mouth disease virus VP1 protein using a replication-competent recombinant canine adenovirus type 2 elicits a humoral antibody response in a porcine model. Viral Immunol 2006, 19:202-209.
35. Lin C.F., Wan S.W., Cheng H.J., Lei H.Y., Lin Y.S. Autoimmune pathogenesis in dengue virus infection. Viral Immunol 2006, 19:127-132.
36. Blaney J.J., Matro J.M., Murphy B.R., Whitehead S.S. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005, 79:5516-5528.
37. Abd-Jamil J., Cheah C.Y., Abubakar S. Dengue virus type 2 envelope protein displayed as recombinant phage attachment protein reveals potential cell binding sites. Protein Eng Des Sel 2008, 21:605-611.
38. Chavez J.H., Silva J.R., Amarilla A.A., Moraes F.L. Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization. Biologicals 2010, 38:613-618.
39. Johnson B.W., Chambers T.V., Crabtree M.B., Bhatt T.R., Guirakhoo F., Monath T.P., et al. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am J Trop Med Hyg 2002, 67:260-265.
40. Consogno G., Manici S., Facchinetti V., Bachi A., Hammer J., Conti-Fine B.M., et al. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 2003, 101:1038-1044.
41. Gauduin M.C. Intracellular cytokine staining for the characterization and quantitation of antigen-specific T lymphocyte responses. Methods 2006, 38:263-273.
42. Zhu X., Gadgil A.S., Givelber R., George M.P., Stoner M.W., Sciurba F.C., et al. Peripheral T cell functions correlate with the severity of chronic obstructive pulmonary disease. J Immunol 2009, 182:3270-3277.
43. Chen W., Huang L. Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol Pharm 2008, 5:464-471.
44. Innis B.L., Eckels K.H. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 2003, 69:1-4.
45. Yamanaka A., Konishi E. A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells. Vaccine 2009, 27:3735-3743.
46. Wang W.K., Sung T.L., Tsai Y.C., Kao C.L., Chang S.M., King C.C. Detection of dengue virus replication in peripheral blood mononuclear cells from dengue virus type 2-infected patients by a reverse transcription-real-time PCR assay. J Clin Microbiol 2002, 40:4472-4478.